

# Other Cancer Type Radiopharmaceuticals Radiation Therapy Worksheet (As of 25 March 2019)

This worksheet is to be used for treatment involving Radiopharmaceuticals. If external beam radiation therapy is being planned for treatment of the liver, please use the appropriate cancer type worksheet. If the request is for SIRT or Xofigo, please use the appropriate physician worksheet.

Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.

For NON-URGENT requests, please complete this document for authorization along with any relevant clinical documentation requested within this document (i.e. radiation therapy consultation, comparison plan, etc.) before submitting the case by web, phone, or fax. Failure to provide all relevant information may delay the determination. Phone and fax numbers can be found on eviCore.com under the Guidelines and Fax Forms section. You may also log into the provider portal located on the site to submit an authorization request. **URGENT (same day) requests must be submitted by phone.**

|                                                                                                                                                                                                                                                                                                                                              |                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| <b>Patient name:</b>                                                                                                                                                                                                                                                                                                                         |                                                                                                              |
| <b>What is the radiopharmaceutical start date (mm/dd/yyyy)?</b>                                                                                                                                                                                                                                                                              | ____ / ____ / ____                                                                                           |
| 1.                                                                                                                                                                                                                                                                                                                                           | Which radiopharmaceutical will be used?                                                                      |
|                                                                                                                                                                                                                                                                                                                                              | <input type="checkbox"/> Iodine-131 (I-131) <input type="checkbox"/> Strontium-89 (Sr-89)                    |
|                                                                                                                                                                                                                                                                                                                                              | <input type="checkbox"/> Lutetium-177 (Lu-177 ; Lutathera®) <input type="checkbox"/> Samarium-153 (Sm-153)   |
|                                                                                                                                                                                                                                                                                                                                              | <input type="checkbox"/> Ibritumomab Tiuxetan (Zevalin®) <input type="checkbox"/> Iobenguane I-131 (Azedra®) |
| <p><b><i>If Lutetium-177 (Lu-177 ; Lutathera®) was selected, please continue to page 2.</i></b></p> <p><b><i>If Iobenguane I-131 (Azedra®) was selected, please continue to page 4.</i></b></p> <p><b><i>Otherwise, please submit the following with this completed worksheet.</i></b></p> <p style="margin-left: 40px;">1. Consult Note</p> |                                                                                                              |

# Lutetium-177 (Lu-177 ; Lutathera®) Radiation Therapy Worksheet (As of 25 March 2019)

Lutathera is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic and bronchopulmonary neuroendocrine tumors.

|     |                                                                                                                                                                                                            |                                                          |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| 1.  | Does the individual have a somatostatin receptor-positive gastroenteropancreatic or bronchopulmonary neuroendocrine tumor?                                                                                 | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 2.  | Has or will treatment with SIRT be given?                                                                                                                                                                  | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 3.  | Will the individual be receiving chemotherapy or other systemic therapy with or following treatment with Lutetium-177?                                                                                     | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 4.  | Has Lutetium-177 been given previously?                                                                                                                                                                    | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 5.  | Does the individual have one of the following?<br><br><input type="checkbox"/> Metastatic disease<br><input type="checkbox"/> Locally advanced inoperable disease<br><input type="checkbox"/> Other: _____ |                                                          |
| 6.  | Is the individual progressing on current therapy?                                                                                                                                                          | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 7.  | What is the individual's creatinine (mg/dL)?                                                                                                                                                               | _____                                                    |
| 8.  | What is the individual's creatinine clearance (mL/min)?                                                                                                                                                    | _____                                                    |
| 9.  | What is the individual's hemoglobin (Hgb)?                                                                                                                                                                 | _____                                                    |
| 10. | What is the individual's white blood cell (WBC) count?                                                                                                                                                     | _____                                                    |
| 11. | What is the individual's platelet count?                                                                                                                                                                   | _____                                                    |
| 12. | What is the individual's Ki-67?                                                                                                                                                                            | _____                                                    |
| 13. | What is the individual's total bilirubin (mg/dL)?                                                                                                                                                          | _____                                                    |
| 14. | Has the individual discontinued long acting somatostatin analogs (i.e. long-acting octreotide) at least 4 weeks prior to treatment starting?                                                               | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 15. | Has the individual discontinued short acting somatostatin analogs (i.e. short-acting octreotide) at least 24 hours prior to treatment starting?                                                            | <input type="checkbox"/> Yes <input type="checkbox"/> No |

***Continued on next page***

# Lutetium-177 (Lu-177 ; Lutathera®) Radiation Therapy Worksheet (As of 25 March 2019)

Lutathera is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic and bronchopulmonary neuroendocrine tumors.

***Please submit the following with this completed worksheet:***

- 1. Radiation Oncology or Nuclear Medicine Consult Note*
- 2. Documentation of the above lab values*

8. Note any additional information in the space below.

|  |  |
|--|--|
|  |  |
|--|--|

# Iobenguane I-131 (Azedra®) Radiation Therapy Worksheet (As of 25 March 2019)

High-specific-activity (HSA) iobenguane I-131 (Azedra®) is approved for the treatment of adult and pediatric patients 12 years or older with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.

|     |                                                                                                                                                   |                                                          |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| 1.  | Does the individual have a diagnosis of iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma? | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 2.  | Is the individual inoperable?                                                                                                                     | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 3.  | Has the individual failed prior therapies?                                                                                                        | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 4.  | Is the individual a candidate for chemotherapy?                                                                                                   | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 5.  | Is the individual on a stable anti-hypertensive regimen?                                                                                          | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 6.  | What is the individual's creatinine clearance (mL/min)?                                                                                           | _____                                                    |
| 7.  | What is the individual's platelet count?                                                                                                          | _____                                                    |
| 8.  | What is the individual's absolute neutrophil count (ANC)?                                                                                         | _____                                                    |
| 9.  | What is the individual's AST?                                                                                                                     | _____                                                    |
| 10. | What is the individual's ALT?                                                                                                                     | _____                                                    |
| 11. | What is the individual's total bilirubin (mg/dL)?                                                                                                 | _____                                                    |
| 12. | Does the individual have a history of hepatitis or chronic alcohol abuse?                                                                         | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 13. | Does the individual have a history external beam radiation to greater than 25% of bone marrow or a history of whole body radiotherapy?            | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 14. | Does the individual have a history of systemic radiotherapy resulting in myelosuppression within the past 3 months?                               | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 15. | What is patient's weight in kilograms?                                                                                                            | _____                                                    |

***Continued on next page***

# Iobenguane I-131 (Azedra®) Radiation Therapy Worksheet (As of 25 March 2019)

High-specific-activity (HSA) iobenguane I-131 (Azedra®) is approved for the treatment of adult and pediatric patients 12 years or older with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.

***Please submit the following with this completed worksheet:***

*1. Consultation note*

*2. Documentation of the above lab results*

16. Note any additional information in the space below.

|  |  |
|--|--|
|  |  |
|--|--|